|University of California, Berkeley, BA|
|University of California, Berkeley, BS|
|Massachusetts Institute of Technology (MIT), PhD|
Dr. Hong joined ProQuest in 2001 as an Associate and became a Principal in 2004. Prior to joining ProQuest, Dr. Hong provided technical consultation to the healthcare group at BancBoston Ventures and pursued academic research in molecular biology and chemistry. Most recently, she led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research.
Currently, Dr. Hong serves on the Board of Directors of Agile Therapeutics and represents ProQuest as an observer on the Board of Directors of Predictive Biosciences. In addition, she worked closely with ProQuest portfolio companies Gloucester Pharmaceuticals (acquired by Celgene) and BioRexis Pharmaceutical Corp. (acquired by Pfizer) among others.
Dr. Hong received a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a Ph.D. in biology from the Massachusetts Institute of Technology.